The effect of dulaglutide on body composition in type 2 diabetes mellitus patients on hemodialysis.

Abstract

AIMS:

To evaluate the effect of dulaglutide on body composition in type 2 diabetes mellitus (T2DM) patients undergoing hemodialysis (HD).

METHODS:

Twenty-one T2DM patients on HD, who had been treated with insulin and newly added teneligliptin (N = 10) or dulaglutide (N = 11), were enrolled. Body composition changes, such as fat mass (FM) and skeletal muscle mass (SMM), glycated albumin (GA), and insulin doses were compared before and after six months of treatment with teneligliptin or dulaglutide.

RESULTS:

The percentage changes of GA and insulin doses were comparable between the teneliglipin and dulaglutide groups. Conversely, although FM and SMM did not change in the teneligliptin group (from 15.7 kg to 14.1 kg, P = 0.63 and 18.6 kg to 18.9 kg, P = 0.16, respectively), those in the dulaglutide group significantly decreased (from 21.9 kg to 18.9 kg, P = 0.037 and 21.0 kg to 20.2 kg, P = 0.011, respectively).

CONCLUSIONS:

Six months of dulaglutide treatment significantly reduced not only FM but also SMM, although changes in GA and insulin doses were comparable with those in the teneligliptin group. Dulaglutide may have the effect of promoting sarcopenia; therefore, it may be carefully used in T2DM patients on HD.

• Authors: Takahiro Yajima, Kumiko Yajima, Hiroshi Takahashi, Keigo Yasuda
• Journal: Journal of diabetes and its complications (J Diabetes Complications) Vol. 32 Issue 8 Pg. 759-763 (08 2018) ISSN: 1873-460X [Electronic] United States
• PMID: 29937137 (Publication Type: Journal Article)
• Copyright: Copyright © 2018 Elsevier Inc. All rights reserved.

Chemical References

• 3-(4-(4-(3-methyl-1-phenyl-1H-pyrazol-5-yl)piperazin-1-yl)pyrrolidin-2-ylcarbonyl)thiazolidine
• Immunoglobulin Fc Fragments
• Pyrazoles
• Recombinant Fusion Proteins
• Thiazolidines
• Glucagon-Like Peptides
• dulaglutide

Topics

• Aged
• Body Composition (drug effects)
• Diabetes Mellitus, Type 2 (complications, drug therapy, therapy)
• Diabetic Nephropathies (drug therapy, metabolism, therapy)
• Female
• Glucagon-Like Peptides (analogs & derivatives, therapeutic use)
• Humans
• Immunoglobulin Fc Fragments (therapeutic use)
• Male
• Middle Aged
• Pyrazoles (therapeutic use)
• Recombinant Fusion Proteins (therapeutic use)
• Renal Dialysis
• Renal Insufficiency, Chronic (complications, metabolism, therapy)
• Sarcopenia (etiology)
• Thiazolidines (therapeutic use)